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The balding industry is worth billions of US 
dollars globally (Allied Analytics LLP, 2019; 
Conrad et al., 2010), with hair transplants alone 
projected to increase in worth from 8 to 12 bil-
lion US dollars by 2026 (Allied Analytics LLP, 
2019). Whilst health psychology aims to pro-
mote people’s wellbeing, it may also have facil-
itated the growth, actions and, ultimately, harm 
caused by baldness-, tobacco-, and other- com-
mercial industries (e.g. Craig et al., 2020; 
Curtis, 2002; Marks and Buchanan, 2020; 
Ogden, 2019; Pelosi, 2019). More specifically, 
psychology may have facilitated the commer-
cial balding industry through the medicalization 
of baldness. Baldness (also known as androge-
netic alopecia or AGA) typically refers to the 
common occurrence of loss of hair among men 
that is not caused by an illness (NHS, 2018). It 
results in no physically harmful or life-limiting 
consequences (Draper, n.d.; Gonul et al., 2018; 
NHS, 2018; Peled, 2004; Tang et al., 2000). 
Nonetheless, it is medicalized1 where it is trans-
formed into a disease largely on the premise 
that it is profoundly psychosocially distressing 
(British Association of Hair Restoration 
Surgeons, 2019; Cash, 2010). The disease sta-
tus of baldness can then be used to promote 
“commercial interventions” (including pharma-
ceuticals, surgery, wigs, or other related prod-
ucts) as medical “treatments”. For example, the 
European Dermatology Forum guidance 
(Blumeyer et al., 2011; Kanti et al., 2018) pro-
vided to those who provide baldness commer-
cial interventions (e.g. surgeons, dermatologists, 
etc. hereafter referred to as practitioners) refers 
to baldness using disease language and implic-
itly advocates for pharmaceutical and surgical 
interventions whilst also emphasizing the 
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psychological impact of balding: “Independent 
of age and gender, patients diagnosed with 
androgenetic alopecia undergo significant 
impairment in their quality of life” (Blumeyer 
et al., 2011: s1).2 Yet this guidance relies on 
just two, heavily cited, studies (Alfonso et al., 
2005; Cash et al., 1993) whose results do not 
actually support the assertion that baldness 
brings about significant psychological dis-
tress. Specifically Cash et al. (1993: 567) note 
“balding men actively cope with their distress” 
and Alfonso et al. (2005) actually found that 
>76% of participants never used baldness 
interventions, did not feel having more hair 
would make them more desirable to their part-
ner and were not dissatisfied with their per-
sonal appearance.3 Despite claims that balding 
causes a significant psychosocial impact, the 
evidence of this is conflicting and poor quality. 
Specifically, studies often use non-validated 
measures, do not reference published norms or 
use a non-balding control group when assess-
ing the impact among balding men impeding 
fair interpretation. Of those assessing the 
impact more soundly, some studies show no 
impact of balding (Cash et al., 1993; Passchier, 
1998; Tas et al., 2018) with others showing an 
impact (Wang et al., 2018; Yamazaki et al., 
2011).
Direct and indirect mechanisms for medical-
izing baldness have been identified. For example, 
anti-baldness commercial campaigns indirectly 
medicalize baldness depicting it as something 
that is isolating, depressing, and stigmatized 
(Harvey, 2013; Moynihan et al., 2002).4 Baldness 
is also directly medicalized by using scientific, 
technical, and medical language to frame it as a 
“devastating disease” and indirectly by the pro-
motion of pharmaceutical drugs (and sometimes 
hair transplant surgery) as “treatments” with 
no- or minimal-reference to their limitations 
(Conrad, 2007; Harvey, 2013; Moynihan et al., 
2002). In addition, research has promoted bald-
ness medicalization through the use of flawed 
methodologies and pharmaceutical influence 
(Jankowski, 2014).
There are several reasons why systematically 
assessing the medicalization of baldness through 
psychosocial research is important. First, the 
above medicalization evidence, whilst useful, is 
“selective and preliminary” (Moynihan et al., 
2002: 900). Second, research like that on bald-
ness has been “flooded” with conflicting find-
ings to generate as much confusion about the 
state of illnesses, interventions, and benign bod-
ily processes as possible, a systematic examina-
tion is thus necessary (Bero, 2017: 15). Third, 
balding men must give informed consent if 
electing to use commercial interventions and 
“informed consent means being informed about 
medicalization and disease mongering” 
(Moynihan et al., 2002: 900). Finally, research 
may be used to bolster the credentials and objec-
tivity of baldness practitioners even if not being 
read directly by men themselves.
The current study
This study sought to systematically assess male 
baldness medicalization by extracting data from 
a recent systematic review (which synthesizes 
the findings and methods of the psychosocial 
impact of baldness research; Frith and 
Jankowski, 2020). In contrast the current study, 
focuses on key mechanisms of baldness medi-
calization and has the following aims:
1. To assess the extent of baldness com-
mercial conflicts of interest
2. To assess if baldnessis represented as a 
disease
3. To assess if intervention-orientated par-
ticipants are disproportionately recruited
4. To assess if commercial intervention-
sare advocated
5. To assess if intervention limitations 
areacknowledged
Method
Search strategy and study selection
This paper is based on a systematic review 
(registered here: Frith and Jankowski, 2020; 
https://osf.io/uvzp9), which examined the 
published evidence of baldness’psychosocial 
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impact among men.5 The Psychology Cross 
Search electronic database was systematically 
searched on the 9th November 2020 by com-
bining terms for baldness, men, and psychoso-
cial outcomes without date parameters but 
limited to English-language texts. The follow-
ing inclusion criteria were applied: (i) the 
study included balding male participants; (ii) 
the study reported the outcomes of most of the 
male balding participants; and (iii) the publi-
cation reported original empirical research. 
Study selection was performed independently 
by both authors in three screening stages from 
titles to full text papers. Pilot screening and 
discussions to resolve uncertainties were also 
conducted.
Data extraction
For the purposes of this paper, data regarding 
indicators of medicalization (conflicts of inter-
est, baldness representation, sample biases, and 
intervention implications) identified through 
previous research (Conrad, 2007; Harvey, 2013; 
Jankowski, 2014; Moynihan et al., 2002) were 
extracted from the 37 studies in the systematic 
review. To provide context, other data extracted 
includes study characteristics (e.g. geographic 
location, study design), sample details (sample 
size, mean age, and other demographics), and a 
study quality score6 (based on a modified AXIS 
tool; Downes et al., (2016) where scores 0–5 = 
Low; 6–10 = Moderate; and 11–14 = High). 
Narrative results are presented below to review 
the studies (in line with: Liu et al., 2018) and 
details are summarized in Table 1.
Data availability
The authors confirm that the data supporting the 
findings of this study are available within the 
article (and/or) its supplementary materials 
which are available at the Open Science 
Framework (doi: 10.17605/OSF.IO/RZP47). 
These include the PRISMA study protocol of 




Disclosure of baldness commercial 
conflicts of interest
Seven studies reported no conflicts of interest 
or commercial funding (Gonul et al., 2018; 
Gupta et al., 2019; Mubki et al., 2019; Rahimi-
Ardabili et al., 2006; Russo et al., 2019; Sawant 
et al., 2010; Tas et al., 2018), 12 did not disclose 
(Bade et al., 2016; Camacho and García-
Hernández, 2002; Danyal et al., 2018; Franzoi 
et al., 1990; Ghimire, 2018; Karaman et al., 
2006; Maffei et al., 1994; Molina-Leyva et al., 
2016; Tahir et al., 2013; Tang et al., 2000; Wells 
et al., 1995; Yamazaki et al., 2011), and the 
remaining 18 indicated funding or some other 
potential conflict of interest.
As not all journals required these disclosures, 
closer inspection of the funding source, the 
author’s profiles and affiliations was conducted. 
In view of even subtle commercial influences in 
dermatology being (a) common (Batalla et al., 
2011; Perlis et al., 2005), (b) leading to more 
commercially favorable results (Batalla et al., 
2011; Perlis et al., 2005; Williams et al., 2006), 
and (c) yet often not being disclosed (Anstey, 
2018; Batalla et al., 2011) and in line with best 
practice dermatological standards (Anstey, 
2018; British Association of Dermatologists, 
2016b), studies were deemed to likely have a 
conflict of interest if explicit evidence suggested 
at least one (co)author (or co(author)’s affiliated 
employer or the study’s commercial funders) 
provided baldness interventions.
Studies that likely do not have conflict 
of interests
Six studies were authored or co-authored by a 
dermatologist but were not obviously associ-
ated with a clinic or practise providing baldness 
interventions (Camacho and García-Hernández, 
2002; Danyal et al., 2018; Rahimi-Ardabili 
et al., 2006; Tas et al., 2018; Wang et al., 2018; 
Yamazaki et al., 2011). Two studies appeared to 
be authored by academics working for an aca-
demic institution (Franzoi et al., 1990; Wells 
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et al., 1995) In total these eight studies were 
deemed likely baldness commercial conflict of 
interest free.
Studies that likely had conflict of 
interests
Fifteen studies (41%) reported some commer-
cial funding (or commercial incentives: Kranz, 
2011) from companies that sold baldness prod-
ucts (e.g. Merck, The Upjohn Company, etc.; 
Alfonso et al., 2005; Budd et al., 2000; Cash, 
1992, 2009; Cash et al., 1993; DeMuro-Mercon 
et al., 2000; Girman et al., 1998; Gosselin, 
1984; Lulic et al., 2017; Passchier et al., 1988, 
1989, 2006; Tabolli et al., 2013; van der Donk 
et al., 1991).
A further 14 studies (38%) very probably 
had at least one (co)author who directly (e.g. as 
a dermatologist or hair transplant surgeon) or 
indirectly (via their employer) provided bald-
ness interventions at the time of the research.7 
Seven of these studies appeared to contravene 
the disclosure requirements of their respective 
journals by not declaring these potential con-
flicts of interest. The journals were: Journal of 
Nepal Medical Association (Ghimire, 2018), 
Anais Brasileiros de Dermatologia (Gonul 
et al., 2018), International Journal of Trichology 
(Gupta et al., 2019), Journal of Cosmetic 
Dermatology (Liu et al., 2018), Egyptian 
Journal of Dermatology and Venereology 
(Mubki et al., 2019), Journal of the European 
Academy of Dermatology and Venereology 
(Russo et al., 2019), and International Journal 
of Trichology (Sawant et al., 2010). Perhaps 
indicating changing disclosure standards, the 
remaining studies appeared to publish in jour-
nals that did not require disclosures (Bade et al., 
2016; Han et al., 2012; Karaman et al., 2006; 
Maffei et al., 1994; Molina-Leyva et al., 2016; 
Tahir et al., 2013; Tang et al., 2000). Perhaps 
the most explicit example of a hidden conflict 
of interest was from Liu et al. (2016: 1441) who 
stated in the Journal of Cosmetic Dermatology 
that “None of the authors has a financial inter-
est in any of the products or devices mentioned 
in this manuscript.” However the study is 
co(authored) by Xingdong Li, a hair transplant 
surgeon as indicated by his stated affiliation to 
the “Kafuring Hair Transplant Hospital” (Liu 
et al., 2016: 1441) and also as he is the founder 
of a chain of 33 hair transplant hospitals in 
China (Barley Microneedle Hair Transplant 
Hospital, n.d.). Thus Li explicitly does have a 
financial interest in hair transplant products and 
indeed could gain financially from any balding 
men reading his (co)authored work that states 
“Hair transplantation significantly elevated 
self-esteem level and increased satisfaction 
with appearance of AGA patients” (p. 1441) 
and “Cosmetic surgery is an effective way to 
improve patients’ appearance and psychologi-
cal state” (p. 1446). Full details of these poten-
tial conflicts of interests and their disclosure is 
in Table 1.
To summarize, of the 37 studies, 29 (78%) 
likely had explicit conflicts of interest in that 
their funding or incentives were provided by a 
company who profited from the sale of bald-
ness products or they were (co)authored by an 
individual whose employer provided baldness 
interventions.
Is baldness defined as a medical 
problem?
Five studies (14%) fully medicalized baldness 
referring to it as a disease (Passchier et al., 
1989; Rahimi-Ardabili et al., 2006; Russo et al., 
2019; Sawant et al., 2010; Tahir et al., 2013). 
Sixteen studies (43%) moderately medicalized 
baldness where they referred to it as a disorder 
or condition, participants as patients (even if 
not recruited in a medical setting) and/or 
described baldness as having an underlying 
genetic or hormonal basis8 (Bade et al., 2016; 
Budd et al., 2000; Cash, 2009; Danyal et al., 
2018; Ghimire, 2018; Girman et al., 1998; 
Gupta et al., 2019; Han et al., 2012; Karaman 
et al., 2006; Kranz, 2011; Liu et al., 2018; Lulic 
et al., 2017; Maffei et al., 1994; Mubki et al., 
2019; Tabolli et al., 2013). Six studies (16%) 
mildly medicalized baldness where it was not 
defined as a disease, condition or disorder but 
medical terms were used as context to baldness 
10 Journal of Health Psychology 00(0)
such as “diagnosis,” “treatments,” or “suffering 
from” (Camacho and García-Hernández, 2002; 
Molina-Leyva et al., 2016; Passchier et al., 
1988, 2006; van der Donk et al., 1991; Wang 
et al., 2018).
Ten studies (27%) did not medicalize bald-
ness (Cash, 1992; Cash et al., 1993; DeMuro-
Mercon et al., 2000; Franzoi et al., 1990; Gonul 
et al., 2018; Gosselin, 1984; Tabolli et al., 2013; 
Tang et al., 2000; Tas et al., 2018; Wells et al., 
1995; Yamazaki et al., 2011). Six simply did not 
define baldness. Four included an acknowl-
edgement that baldness was not a disease. Three 
did this explicitly. Specifically, Gonul et al. 
(2018: 651) noted that baldness “is biologically 
benign and is not a disease in the conventional 
sense,” Tang et al. (2000: 204) noted “it is not a 
disease in the medical sense of the word,” and 
Yamazaki et al. (2011: 773) noted that baldness 
“is not involved in systemic diseases.” One final 
study was more suggestive about the potential 
non-disease status of baldness, noting “it is a 
frequent complaint among adults, which mostly 




One study (3%) did not report enough sampling 
details to determine if their participants were 
intervention orientated (n = 175; Karaman 
et al., 2006). Twenty-five studies (68%) repre-
senting 6,240 participants (59% of the entire 
sample) recruited participants who were explic-
itly seeking or undergoing interventions for 
baldness whether transplant, pharmaceutical, or 
cosmetic product (see Table 1). Participants 
from these studies were largely recruited from a 
dermatology clinic (e.g. Gonul et al., 2018) or 
through their interest in a minoxidil trial as 
advertised in local media (Passchier et al., 1988, 
1989). Therefore, these participants were more 
likely to be baldness distressed than other bald 
men who did not take part in these studies.
Eleven studies (30%) recruited participants 
regardless of interest in baldness interventions 
forming a less biased assessment of the impact 
of baldness. Five of these samples were typi-
cally large, amounting to 3,604 participants 
(22% of the total participants) and were 
recruited in order to form a population repre-
sentative sample (Alfonso et al., 2005; Budd 
et al., 2000; DeMuro-Mercon et al., 2000; 
Girman et al., 1998; Tang et al., 2000). The 
remaining six studies recruited participants 
through convenience sampling, and ostenta-
tiously not because they were actively seeking 
or undergoing interventions (Cash, 1992; 
Danyal et al., 2018; Franzoi et al., 1990; Kranz, 
2011; Passchier et al., 2006; Wells et al., 1995). 
These samples amounted to 565 participants 
(5% of the total sample). For example, two 
studies recruited participants observed by the 
researchers to have baldness (from a dermatol-
ogy clinic but only if they attended for non-
baldness related issues; Passchier et al., 2006 
and from an airport; Franzoi et al., 1990). These 
11 studies comprised a less biased assessment 
of baldness’ impact given most balding men do 
not seek out interventions (Alfonso et al., 2005; 
DeMuro-Mercon et al., 2000; Kranz, 2011; 
Tang et al., 2000).
Does this psychosocial impact 
research recommend commercial 
interventions?
More than a third of the studies (n = 14) did not 
make explicit intervention recommendations. 
Perhaps this was because of the brevity of the 
papers (Camacho and García-Hernández, 2002; 
DeMuro-Mercon et al., 2000; Franzoi et al., 
1990; Ghimire, 2018; Girman et al., 1998; 
Gonul et al., 2018; Gosselin, 1984; Karaman 
et al., 2006; Passchier et al., 1988, 1989; 
Rahimi-Ardabili et al., 2006; Sawant et al., 
2010; van der Donk et al., 1991; Wells et al., 
1995). It would be a mistake nonetheless to 
consider these studies free of intervention 
implications as some were evaluation studies 
and reported beneficial effects of the interven-
tion, even unduly. For example, Passchier et al. 
(1988) reported non-significant results as if 
Jankowski and Frith 11
they were significant in their abstract (which is 
more often read than the body of the paper) for 
minoxidil: “More psychological improvement, 
with regard to hair problems, social discomfort, 
and self-esteem occurred in the minoxidil group 
than in the placebo group.” (p. 441) despite the 
results actually showing two or all (given the 
low t value) of these three benefits were non-
significant (“the responders were more 
improved than the nonresponders with respect 
to self-esteem (t(83) = 1.87, p < 0.05), overall 
social discomfort (a trend: p < 0.10) and hair 
problems (NS)” (p. 444).
Of the remaining studies that recommended 
interventions (n = 23), one study was alone in 
advocating psychological therapy instead of 
cosmetic or other interventions on the basis that 
men who accepted their baldness showed less 
distress (4%; Kranz, 2011: 347): “Responsible 
practitioners and dermatologists might be cor-
rect when hesitating to medically or even surgi-
cally treat balding in young men. They should 
rather encourage their patients to come to 
terms with their baldness – not least because of 
limited treatment options on the one side and 
patient’s high expectations about treatment out-
comes on the other side.”
Five studies (22%) explicitly advocated 
counseling or contact with a professional psy-
chologist but only as an adjunct to commercial 
(cosmetic or surgical) interventions (Mubki 
et al., 2019; Russo et al., 2019; Tahir et al., 
2013; Tas et al., 2018; Wang et al., 2018). Ten 
studies (43%) advocated psychological support 
as an adjunct to commercial interventions but 
not from a professional psychologist or counse-
lor (Bade et al., 2016; Cash, 1992, 2009; Cash 
et al., 1993; Danyal et al., 2018; Gupta et al., 
2019; Han et al., 2012; Lulic et al., 2017; 
Molina-Leyva et al., 2016; Tabolli et al., 2013). 
The psychological support recommended was 
typically poorly defined (e.g. “an empathic 
understanding of these patients’ concerns is 
essential to effective management”; Cash, 1992: 
930 and “Psychosocial measures need to be 
installed”; Danyal et al., 2018: 406). One of the 
few more concrete suggestions was “a brief, 
structured patient questionnaire” to screen 
participants (Cash, 2009: 1819) however no 
further recommendations indicated what practi-
tioners should do after screening balding men 
(e.g. whether to refuse them intervention). 
Other studies (e.g. Lulic et al., 2017) noted phy-
sicians should make time for discussions with 
men affected psychologically, usually in terms 
of intervention expectations and decisions (i.e. 
not necessarily dealing with psychosocial issues 
and assuming intervention is the correct 
approach). Furthermore, some of these studies 
recommended or implied commercial interven-
tions were the routes to resolve psychological 
issues associated with baldness (Cash, 1992; 
Danyal et al., 2018; Han et al., 2012). For exam-
ple: “Cosmetic treatments may also be used as 
a remedy for the psychological concern arising 
due to baldness” (Danyal et al., 2018: 406).
Seven studies (30%) explicitly recommended 
commercial interventions. This was unspecified 
as just “treatments” (Alfonso et al., 2005; Maffei 
et al., 1994; Passchier et al., 2006), surgery, drug 
therapy, wigs, and hair styling (Budd et al., 
2000), cosmetic surgery (Liu et al., 2018), finas-
teride and minoxidil (Tang et al., 2000), and fin-
asteride (Yamazaki et al., 2011). Commercial 
interventions were occasionally implicitly rec-
ommended: “The present study suggests that 
oral finasteride improves the QOL of patients 
but does not necessarily alleviate their anxie-
ties. The guidelines for the treatment of AGA 
should take account of the patients’ QOL” 
(Yamazaki et al., 2011: 777). More often this 
was explicit. For example, Passchier et al. 
(2006: 228) noted: “For those who have prob-
lems, a prompt communication between the man 
and a dermatologist should be encouraged after 
the discovery, as there are now effective treat-
ment options available for baldness and the ear-
lier the treatment, the better.”
Does this psychosocial impact 
research acknowledge intervention 
limitations?
Of the 25 studies that included a reference to 
interventions, eight (32%; Bade et al., 2016; 
Cash, 2009; Kranz, 2011; Lulic et al., 2017; 
12 Journal of Health Psychology 00(0)
Molina-Leyva et al., 2016; Mubki et al., 2019; 
Passchier et al., 1989; Rahimi-Ardabili et al., 
2006) gave some space to reporting limitations 
(e.g. cost, potential inefficacy, or side effects). 
This was usually less space than intervention 
benefits, but it was nonetheless more than other 
studies. For example, in their introduction Bade 
et al. (2016: 12900) noted “In many cases the 
results of treatment are unsatisfactory while on 
the other hand, people have high expectations, 
hence counselling is very important in these 
cases.” Kranz (2011) and Mubki et al. (2019) 
noted the general limitations of interventions, 
Lulic et al. (2017) assessed the importance of 
“potential side effects” (unspecified) and cost of 
interventions on decision making, Molina-
Leyva et al. (2016) reported on the sexual dys-
function side effects of finasteride, Passchier 
et al. (1989: 12) acknowledged a “transient and 
partial libido loss” in 9.4% of participants who 
had taken minoxidil and Rahimi-Ardabili et al. 
(2006) reported on the side effects of finasteride. 
Finally, Cash (2009: 1818) reported that previ-
ous research had found finasteride and minoxi-
dil efficaciousness was only “relatively high.”
Three studies acknowledged intervention 
limitations but only for fringe or historical inter-
ventions in contrast to finasteride, minoxidil, or 
surgery (12%; Gupta et al., 2019; Han et al., 
2012; Tang et al., 2000). For example, Tang 
et al. (2000: 405) noted the potential ineffective-
ness and cost of interventions but only of “herbs, 
hair centers. . ..[and] traditional Chinese medi-
cine” and instead advocated for the “effective 
help available (e.g. topical minoxidil(16) or 
oral finasteride(17)).” Han et al. (2012: 317) 
warned against “inappropriate and unproven 
therapies that are available in nonmedical set-
tings. . . Therefore, it is necessary to provide 
patients with correct information that is medi-
cally approved.” Gupta et al. (2019: 150–151) 
acknowledged that the “history of the treatment 
of AGA has more than its fair share of tricho-
quackery,” but continued to advocate for com-
mercial interventions.
Fourteen studies did not report any limitations 
when mentioning interventions (56%; Alfonso 
et al., 2005; Budd et al., 2000; Camacho and 
García-Hernández, 2002; Cash, 1992; Cash 
et al., 1993; Danyal et al., 2018; Liu et al., 2018; 
Maffei et al., 1994; Passchier, 1998; Passchier 
et al., 2006; Tas et al., 2018; van der Donk et al., 
1991; Wang et al., 2018; Yamazaki et al., 2011). 
These studies implied commercial interventions 
were universally beneficial and the default, 
responsible, response to baldness (e.g. by assess-
ing how much awareness men had around inter-
ventions, Budd et al., 2000) and urged future to 
research to explore what “is needed into the fac-
tors affecting men’s willingness to seek treatment 
for baldness” (Alfonso et al., 2005: 1835). Other 
studies noted only benefits of these commercial 
interventions: “Consequently, an improvement in 
alopecia induced by medical treatment could 
reduce the psychopathologic reactive symptoms 
by restoring the body image and its interpersonal 
correlates” (Maffei et al., 1994: 871) and 
“Cosmetic surgery is an effective way to improve 
patients’ appearance and psychological state” 
(Liu et al., 2018: 1446).
Discussion
Commercial influences on health are increas-
ingly widespread (de Lacy-Vawdon and 
Livingstone, 2020; Kickbusch et al., 2016) and 
psychology’s facilitation of this has come under 
recent scrutiny (Cosgrove and Wheeler, 2013; 
Marks and Buchanan, 2020; Ogden, 2019; 
Pelosi, 2019). The medicalization of baldness 
represents another way psychology facilitates 
commercial influences of health, through the 
claim that baldness is psychologically devastat-
ing and thus comprises a medical disorder 
requiring commercial interventions to remedy 
(Conrad, 2007; Harvey, 2013; Jankowski, 2014; 
Moynihan et al., 2002). This study sought to 
systematically explore the mechanisms through 
which baldness is medicalized in research 
assessing its psychosocial impact.
The dominance of baldness 
commercial conflicts of interest
The medicalization of baldness may arise indi-
rectly from commercial conflicts of interest 
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where the framing of baldness, the implica-
tions, and the conclusions in research are more 
commercially favorable. Analyses of dermatol-
ogy research (Batalla et al., 2011; Perlis et al., 
2005; Williams et al., 2006) and other research 
(Cosgrove and Wheeler, 2013; Lundh et al., 
2017) shows commercial influences are signifi-
cantly related to results and recommendations 
that promote commercial interventions. This is 
supported by one baldness study’s candid 
admission that commercial influence means 
one will “present a [less] balance[d] picture of 
the likely effects of treatment” (Passchier et al., 
1989: 330). Most studies had commercial con-
flicts of interest (n = 29; 78%), although 11 of 
these studies did not disclose, confirming previ-
ous reports that regulation (such as disclosure) 
is minimal or ineffective (Anstey, 2018; Batalla 
et al., 2011; Cosgrove and Wheeler, 2013; John 
et al., 2019; Stoll et al., 2020). One common 
commercial funder of the research is Merck 
who have created fake academic journals, have 
forced researchers to sign gagging clauses and 
have made extensive efforts to hide product 
side effects (Edwards, 2009; Goldacre, 2012; 
Levine, 2019). However, pharmaceutical bod-
ies are not the only vested interests in this 
research. Notably many of the authors provide 
baldness services themselves (e.g. transplants). 
Commercial conflicts of interest pervade bald-
ness media and forums (Cosmeticium, 2019; 
Harvey, 2013; Rocknroutlaw, 2019) healthcare 
(Fabbri et al., 2017; Goldacre, 2012) and psy-
chology (Conrad, 2007; Cosgrove and Wheeler, 
2013). The commercial funding behind most of 
this research compellingly demonstrates corpo-
rate determination of health, a challenge to 
health psychology’s aims of promoting a 
healthier society.
The disease framing of baldness
Just three studies had an explicit acknowledge-
ment that baldness was not a disease. The rest 
either did not define baldness or, directly, medi-
calized it (e.g. definitionally). The importance 
of the use of medicalized language is demon-
strated by a recent review (Nickel et al., 2017) 
which found that when more medicalized or 
specific terms were deployed, individuals were 
more favorable to invasive diagnoses or inter-
ventions and rated the condition as more severe 
and experienced more anxiety. The disease 
framing of baldness is one key direct mecha-
nism in which corporations are determining 
health, in this case misrepresenting baldness as 
a disease.
The dominance of intervention-
orientated participants
Of the studies reporting sample details, the 
majority (67%) recruited male participants who 
were already seeking baldness services or prod-
ucts. Whilst this may have been for pragmatic 
reasons, these participants may also be: “more 
concerned about the impact of alopecia on their 
everyday life [relative to other balding men]” 
as some acknowledged (Molina-Leyva et al., 
2016: 46). However, research on representative 
samples of balding men has found between 
75% and 95% have not used or sought baldness 
interventions previously (Alfonso et al., 2005; 
DeMuro-Mercon et al., 2000; Kranz, 2011; 
Tang et al., 2000). By using balding men who 
are already seeking intervention, and thus more 
likely to be distressed than balding men not 
seeking interventions (given distress in repre-
sentative sample studies is relatively low; e.g. 
Alfonso et al., 2005; Kranz, 2011), the research 
indirectly medicalizes baldness by associating 
it with profound psychological distress requir-
ing medical “treatments” to remedy.
Commercial interventions might 
themselves induce poor quality of life
Of the studies that made an intervention recom-
mendation (n = 24), 96% recommended com-
mercial (cosmetic, pharmaceutical, or surgical) 
interventions. This is notable since this research 
is designed to assess the psychosocial impact of 
baldness, often on the presumption this is pro-
found, and yet only one study recommended 
psychosocial interventions (Kranz, 2011). Of 
the studies discussing interventions (n = 30), 
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just eight (27%) including any acknowledge-
ment of the limitations inherent in these inter-
ventions (albeit briefly). The remainder of the 
studies discussed interventions uncritically giv-
ing all or most of the space to discussing their 
benefits. This biased intervention portrayal 
indirectly medicalizes baldness by promoting 
commercial interventions as life-saving bald-
ness “treatments”. This is concerning since all 
interventions, including regulatory-approved 
ones (finasteride and minoxidil), can be ineffi-
cacious, harmful, and expensive (NICE, 2018). 
Surgery carries risk of infection and evidence 
mounts for the existence of “postfinasteride 
syndrome” (Diviccaro et al., 2020; Ganzer and 
Jacobs, 2018; Ganzer et al., 2015) which refers 
to the profound and irreversible sexual, mental, 
and unwanted appearance changes (e.g. devel-
opment of male breast tissue) some men experi-
ence even after no longer taking finasteride. A 
concerted effort to discredit men reporting these 
side effects has been noted (Diviccaro et al., 
2020; Ganzer et al., 2015; Rahimi-Ardabili 
et al., 2006).
Whilst baldness distress is overstated in 
research and elsewhere (Frith and Jankowski, 
2021; Harvey, 2013), a minority of balding 
men may be significantly distressed. It is pos-
sible commercial baldness interventions, if 
safely administered and monitored, provide 
meaningful benefits to these men. Nonetheless, 
bald men should be offered a menu of 
responses, including not intervening, when 
considerig their baldness. In addition, it is 
important that robust psychological work 
which seeks to understand, and alleviate, this 
distress is available. As Peled (2004: 1) notes, 
a medical professional who himself is bald: 
“Certainly, the safest and least invasive way to 
address the psychosocial impact of baldness is 
through psychosocial counselling.” This might 
include psychosocial interventions to promote 
appearance acceptance (e.g. via FaceIt@
Home, Bessell et al., 2012, https://www.facei-
tonline.org.uk/).
It is possible that medicalization of baldness 
itself causes distress rather than baldness per se. 
Kranz (2011) found balding men who did not 
seek commercial interventions for their baldness 
were statistically less distressed than those who 
did. The harmful effects of some interventions, 
notably finasteride, may induce distress among 
balding men that was not present before, directly 
through side effects and indirectly via the way 
they are promoted (by portraying baldness as an 
isolating and suicide-inducing condition tying 
into a wider ‘appearance potent’ culture that 
includes the valorization of a full head of hair; 
Harvey, 2013; Jankowski et al., 2014). In other 
words, distress may occur because of this cul-
ture rather than baldness itself and thus, notably, 
not be alleviated by baldness products or ser-
vices but rather wider, cultural, change. Other 
tentative support that medicalization promotes 
baldness distress comes from the acknowledg-
ment from cosmetic and baldness professionals 
(British Association of Plastic Reconstructive 
and Aesthetic Surgeons, n.d.) that some young 
men are becoming distressed from balding, that 
they do not have, due to aggressive social mar-
keting of commercial interventions, and that 
balding men may experience less distress at the 
moment of discovering their baldness than later 
on (e.g. Alfonso et al., 2005) potentially because 
they are not yet exposed to pervasive baldness 
medicalization.
Limitations
The data reviewed was based on the published 
literature. Medicalization occurs outside of this 
(not least in unpublished and published infor-
mation sources such as gray literature, anti-
baldness product reviews, social media, etc). 
For example, Dorfman et al. (2018) found that 
the majority of plastic surgery social media 
posts by cosmetic surgeons were explicitly self-
promotional (67%) rather than educational 
(33%) and the regulation of this is minimal 
(British Association of Hair Restoration 
Surgeons, n.d.). The assessment of medicaliza-
tion should seek to document and challenge 
this. Further we have not tracked medicaliza-
tion in relation to the development and release 
of baldness products (such as the development 
of finasteride, hair transplants, etc.) through 
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research, which is the research balding men are 
more likely to access (Harvey, 2013).
Conclusion
The results of this review show systematically 
that the research assessing the psychosocial 
impact of balding on men is largely conducted 
by those with commercial vested interests in 
baldness products and services and this research 
medicalizes baldness by defining it as a disease, 
via selective sampling of “intervention-orien-
tated” men, and through the implicit and explicit 
advocacy of cosmetic and pharmaceutical prod-
ucts/services. Such medicalization, through 
psychosocial research, often by psychology 
authors, must be challenged if balding men are 
to provide informed consent in responding to 
their baldness.
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Notes
1. This refers to the “transformation of ordi-
nary processes of life into medical phenom-
ena [through]the invisible and unregulated 
attempts to change public perceptions about 
health and illness to widen markets” (Moynihan 
et al., 2002: 898–900). Medicalization was 
first identified in the 1970s by sociologists 
and disability rights activists (Conrad, 2007; 
Zola, 1972). Key examples of medicalization 
include mental disorders that have limited evi-
dence bases (Cosgrove and Wheeler, 2013), 
non-complicated childbirth and appearance 
“defects” (Conrad, 2007). Medicalization has 
been criticized for being poorly specified and 
for pathologizing expansions in medicine as 
inherently harmful; criticisms that are addressed 
by Conrad et al. (2010) and Hofmann (2016).
2. Similar, albeit qualified, statements are made 
in other guidance. For example, the patient 
information leaflet guidance from the British 
Association of Dermatologists (2016a: 1) notes 
“Hair loss may cause significant psychologi-
cal difficulties” and guidance from the Asian 
Consensus Committee (Lee et al., 2013: 1029) 
notes: “Androgenetic alopecia is often asso-
ciated with a poor self-image and low self-
respect.” Neither statement cites evidence.
3. Alfonso et al.’s (2005) findings are further 
misrepresented in the guidance by noting that: 
“Men who treated their baldness successfully 
reported psychosocial benefits with improve-
ments for self-esteem and personal attractive-
ness” (Kanti et al., 2018: 2). This fails to note 
that 38%–80% of Alfonso et al.’s (2005) par-
ticipants did not “treat baldness successfully”. 
Even among those who did, many (37%–62%) 
did not report psychosocial benefits.
4. This depiction is bolstered by research on bald-
ing stigmatization; some of which supports 
the idea that baldness is associated with some 
negative connotations (such as aging), while 
some show neutral or positive connotations 
(for a review see: Henss, 2001). This campaign 
and research promotes the idea baldness needs 
to be changed rather than stigma and fails to 
account for research showing baldness stigma 
may not translate into meaningful behaviors 
(Sigelman et al., 1990), may be mitigated when 
individuating information about the balding 
person is available (Kranz et al., 2019) or by 
other aspects of appearance such as facial hair 
or glasses (Blaker et al., 2020; Muscarella and 
Cunningham, 1996).
5. Table 1 lists these key findings from the research 
and a fuller synthesis of findings is available in 
Frith and Jankowski (2021).
6. The AXIS tool is a widely used risk of bias 
assessment that is appropriate for cross-sec-
tional studies. It was developed via a system-
atic review of existing tools, a Delphi survey, 
and expert consultation (Downes et al., 2016). 
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It is open access, has accessible guidance and 
is flexible in allowing modifications. Key tool 
criteria include whether the sample size is jus-
tified, whether attrition is noted and whether 
basic data is adequately described. The over-
all quality score of each study is presented 
in Table 1 and full details of each criteria are 




7. All potential conflicts of interests involve (co)
authors of the research where publicly available 
information indicates they or their employer 
currently provides baldness interventions. It is 
likely this was also true at the time the studies 
were published given (a) some studies list the 
employer as the authors’ affiliation (Gonul et al., 
2018; Han et al., 2012; Karaman et al., 2006; 
Liu et al., 2018; Mubki et al., 2019; Russo et al., 
2019; Sawant et al., 2010; Tang et al., 2000), (b) 
some profiles of the (co)authors explicitly indi-
cate years of experience that precedes the study 
publication dates (Bade et al., 2016; Ghimire, 
2018; Gupta et al., 2019; Maffei et al., 1994; 
Molina-Leyva et al., 2016; Tahir et al., 2013), 
and (c) most of these studies were published 
relatively recently (since 2010; two studies were 
not; Maffei et al., 1994; Tang et al., 2000).
8. In this context, research focusing on the genetic 
and hormonal basis of baldness can be read as 
medicalizing because the research fails to note—
as Conrad (2002) points out—how other aspects 
of the body may have genetic or hormonal bases 
though this does not make them a disease (e.g. 
eye color or moderate mood fluctuations).
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